Citations

Clear

634 citation(s) found for "Hall, A".

Outcomes Prognostication for Septuagenarians and Octogenarians Diagnosed with Meningioma: Leveraging National Registry Data for the Development of a Prognostic Model for Survival Prediction in the Elderly Population
Patel, Saarang , Sahyouni, Ronald , Khalessi, Alexander A. , Brown, Nolan J. , Pennington, Zach , Ben‐Haim, Sharona

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803207 Get It

P-709. Risk factors for hypoxia and mechanical ventilation in Respiratory Syncytial Virus (RSV) infections in hospitalized solid organ transplant recipients (SOTR)
Hall, Victoria , Sim, Beatrice , Mayyadah, Alabdely, Mendoza, Maria A. , Dumais, Mitchell , Rodríguez, Raul, Yong, Michelle K. , Yetmar, Zachary A. , Razonable, Raymund R. , Natori, Yoichiro

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.905 Get It

Abstract Background RSV is a common respiratory infection that causes significant morbidity in SOTR. However, risk factors for complications such as hypoxic respiratory failure, mechanical ventilation, and secondary infections have not been well described. Methods This retrospective, international, multicenter cohort study is actively recruiting SOTR hospitalized with RSV. Here, we analyzed data from Mayo Clinic (Rochester, Florida, Arizona), Miami Transplant Institute, Cleveland Clinic, and Royal Melbourne Hospital between 2016 and 2019. Secondary infection was defined as culture positive infection within 90 days of RSV diagnosis. Whenever appropriate, logistic and Cox regression analysis were conducted to identify risk factors. Survival functions were estimated using the Kaplan-Meier method.Figure 1:Forest plots of multivariable logistic regression models for risk factors for A) hypoxia, B) secondary infections, C) mechanical ventilation. Note: all variables included are the ones statistically significant on univariate analysis. Abbreviations: CI, confidence interval; OR, Odds ratio; LRTI: lower respiratory tract infection. Results 233 SOTRs (58.8% male; median, 61 years), including 77 (49.1%) kidney, 23 (9.9%) liver, 79 (33.9%) lung, and 38 (16.3%) heart transplants (Table). Hypoxic respiratory failure, mechanical ventilation, and secondary infection were seen in 98 (42.1%), 23 (9.9%), and 58 (24.9%) patients, respectively. After multivariate analysis, age >60 years, symptoms and imaging evidence of lower respiratory tract infection (LRTI) were associated with oxygen requirement (Figure 1A); similar results were observed in an analysis of the lung transplant cohort only. Risk factors on multivariate analysis for secondary infection include a history of rejection within six months and mechanical ventilation (Figure 1B). Risk factors for mechanical ventilation included age >60 years and LRTI on imaging (Figure 1C) after multivariate analysis. Seventeen (7.3%) patients died within 90 days of diagnosis. Cox univariate analysis identified age >60 years and LRTI on imaging, secondary infections, mechanical ventilation and hypoxia on admission were associated with higher mortality (Figure 2 and 3).Figure 2:Forest plot with Cox proportional hazards models. Note: only univariate results shown, multivariate not done due to low number of events. Conclusion This multicenter study of SOTR hospitalized with RSV identified older age ( >60 years old) as a risk factor for hypoxic respiratory failure, mechanical ventilation and death. Mechanical ventilation and a history if rejection within six months of RSV were associated with increased risk of secondary infections, identifying them as high-risk that needs close surveillance for this complication.Figure 3:Effects of A) Age older than 60 years old and B) mechanical ventilation on 90 day probability of survival after RSV infection Disclosures Michelle Yong, MBBS, FRACP, MPH, PhD, MSD: Grant/Research Support|MSD: Honoraria|Takeda: Advisor/Consultant Yoichiro Natori, MD, Eurofin/Viracor: Honoraria|Nobel Pharma: Advisor/Consultant
Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease
Kornak, John , Staffaroni, Adam M. , Cadwallader, Claire J. , Lago, Argentina Lario , Webb, Julia D, Chen, Coty , Rascovsky, Katya, Miyagawa, Toji , Ramos, Eliana Marisa , Masdeu, Joseph C. , Pressman, Peter , Rademakers, Rosa , Kremers, Walter K. , Darby, Ryan, Pascual, Belén , Ghoshal, Nupur , Mackenzie, Ian R. , Li, Jingyao , Hall, Jacob , Yutsis, Maya, Litvan, Irene , Henderson, Victor W. , Sivasankaran, Rajeev , Worringer, Katie, Domoto-Reilly, Kimiko, Snyder, Allison, Kramer, Joel H. , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L., Domoto‐Reilly, Kimiko , Damme, Philip Van , Casaletto, Kaitlin B , Masdeu, Joseph C , Pascual, Belen , Litvan, Irene , Sivasankaran, Rajeev , Boeve, Brad , Van Damme, Philip , Kremers, Walter K , Domoto-Reilly, Kimiko , Saloner, Rowan , Villeda, Saul , Paolillo, Emily W. , VandeBunte, Anna M. , Pantelyat, Alexander , Tartaglia, Maria Carmela , Bozoki, Andrea C , Younes, Kyan , Lapid, Maria I. , Hsiung, Ging‐Yuek Robin , Worringer, Katie, Loureiro, Joseph , Boeve, Bradley F. , Rojas, Julio C. , Boxer, Adam L.

Mayo Clinic

Brain Communications | January 15, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcae432 | PMID 39816189 Get It

Abstract The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate ‘pro-aging’ or ‘pro-youthful’ effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear. We examined five previously identified brain rejuvenation factors in cerebrospinal fluid of adults with autosomal dominant forms of frontotemporal dementia and sporadic Alzheimer’s disease. Our frontotemporal dementia cohort included 100 observationally followed adults carrying autosomal dominant frontotemporal dementia mutations (Mage = 49.6; 50% female; 43% C9orf72, 24% GRN, 33% MAPT) and 62 non-carriers (Mage = 52.6; 45% female) with cerebrospinal fluid analysed on Somascan, and longitudinal (Mvisits = 3 years, range 1–7 years) neuropsychological and functional assessments and plasma neurofilament light chain. Our Alzheimer’s disease cohort included 35 adults with sporadic Alzheimer’s disease (Mage = 69.4; 60% female) and 56 controls (Mage = 68.8, 50% female) who completed the same cerebrospinal fluid and clinical outcome measures cross-sectionally. Levels of C-C motif chemokine ligand 11, C-C motif chemokine ligand 2, beta-2-micorglobulin, bone gamma-carboxyglutamate protein (aka Osteocalcin) and colony stimulating factor 2 in cerebrospinal fluid were linearly combined into a composite score, with higher values reflecting ‘pro-youthful’ levels. In genetic frontotemporal dementia, higher baseline cerebrospinal fluid rejuvenation proteins predicted slower decline across cognitive, functional, and neurofilament light chain trajectories; estimates were similar across genotypes. In transdiagnostic analyses, higher cerebrospinal fluid rejuvenation proteins associated with better functional, cognitive, and neurofilament light chain outcomes in adults with sporadic Alzheimer’s disease. Proteins with pre-clinical evidence for brain rejuvenation show translational clinical relevance in adults with Alzheimer’s disease and related dementias and warrant further investigation.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Wei, Andrew H. , Marcucci, Guido , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Stelljes, Matthias , Najima, Yuho , Wei, Andrew H , Hill, Jason , Chen, Yi-Bin , Hamadani, Mehdi , Wingard, John R. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Hill, Jason E. , King, Denise, Devine, Steven M.

Mayo Clinic

Blood | January 7, 2025 | Volume: 145 | Issue: 19 | Pages: 2138-2148

10.1182/blood.2024025154 | PMID 39775763 Get It

Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
Investigating the added value of incorporating mammographic density to an integrated breast cancer risk model with questionnaire-based risk factors and polygenic risk score
Mulder, Charlotta , Yang, Xin , Jee, Yon Ho , Gao, Chi , Cao, Yu , Hurson, Amber N. , Vachon, Celine M. , Hall, Per, Antoniou, Antonis C., Kraft, Peter, Choudhury, Parichoy Pal , Eriksson, Mikael , Vachon, Celine M. , Hall, Per N , Antoniou, Antonis C. , Gierach, Gretchen L. , García‐Closas, Montserrat

Mayo Clinic

No container title available | December 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5445786/v1 | PMID 39764121 Get It

Abstract Introduction Incorporation of mammographic density to breast cancer risk models could improve risk stratification to tailor screening and prevention strategies according to risk. Robust evaluation of the value of adding mammographic density to models with comprehensive information on questionnaire-based risk factors and polygenic risk score is needed to determine its effectiveness in improving risk stratification of such models. Methods We used the Individualized Coherent Absolute Risk Estimator (iCARE) tool for risk model building and validation to incorporate density to a previously validated literature-based model with questionnaire-based risk factors and a 313-variant polygenic risk score (PRS). The model was evaluated for calibration and discrimination in three prospective cohorts of European-ancestry women (1,468 cases, 19,104 controls): US-based Nurses’ Health Study (NHS I and II) and Mayo Mammography Health Study (MMHS); and Sweden-based Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA) study. Analyses were done separately for women younger (NHS II, KARMA) and older than 50 years (NHS I, MMHS, KARMA). Improvements in terms of risk stratification and reclassification proportions were assessed among European-ancestry women aged 50–70 years in US and Sweden. Results For women younger and older than 50 years, the model with questionnaire-based risk factors, PRS and density was generally well calibrated across risk with some evidence of miscalibration at the extremes of the risk distribution. Incorporation of density led to modest improvements risk discrimination beyond the model with questionnaire-based risk factors and PRS: the area under the curve (AUC) among younger women was 67.0% (95% CI: 63.5–70.6%) vs. 65.6% (95% CI: 61.9–69.3%) for models with and without density; and 66.1% (95% CI 64.4–67.8%) vs. 65.5% (95% CI: 63.8–67.2%) among older women. The model with density identified 18.4% of US women 50–70 years old ≥ 3% 5-year predicted risk (threshold used for recommending risk-reducing medication in the US), with 42.4% of future cases expected to occur in this group. At this threshold, 7.9% of US women were reclassified by adding density to the model, resulting in the identification of 2.8% of additional future cases. The model with density identified 10.3% of Swedish women ≥ 3% 5-year predicted risk, with 29.4% of future cases expected to occur in this group. At this threshold, 5.3% of women were reclassified with the addition of density, leading to the identification of an additional 4.4% of future cases. Conclusion Integrating density with questionnaire-based risk factors and PRS could potentially identify more women of European-ancestry with elevated risk of breast cancer in the United States and Sweden. Further investigations of the integrated model in non-European ancestry populations are needed prior to considering clinical applications.
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Gupta, Samir , Axell, Lisen, Burke, Carol A. , Chen, Lee-may, Chung, Daniel C. , Clayback, Katherine M, Felder, Seth , Giardiello, Francis M., Gustafson, Susan, Hagemann, Andrea R. , Hall, Michael J. , Idos, Gregory , Joseph, Nora, Kassem, Nawal , Kelly, Kaitlyn, Kieber‐Emmons, AnnMarie, Kupfer, Sonia S., Lang, Katie, Llor, Xavier , Markowitz, Arnold J. , Prats, Mariana Moreno, Niell‐Swiller, Mariana, Pirzadeh‐Miller, Sara , Samadder, N. Jewel , Shibata, David , Swanson, Benjamin , Szymaniak, Brittany M. , Welborn, Jeanna, Wiesner, Georgia L. , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Diwan, Zeenat, Samadder, Niloy Jewel, Gupta, Samir , Burke, Carol A , Hodan, Rachel , Weiss, Jennifer M. , Chung, Daniel C., Foda, Zachariah H. , Grady, William M. , Hampel, Heather , Katona, Bryson W , Outlaw, Darryl Alan , Stanich, Peter P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 695-711

10.6004/jnccn.2024.0061 | PMID 39689429 Get It

Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing. This manuscript also describes recent updates to these guidelines regarding de-implementation of colon cancer screening in individuals with CHEK2 pathogenic/likely pathogenic variants, based on the most up-to-date evidence regarding the association between CHEK2 pathogenic/likely pathogenic variants and colon cancer risk.
Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)
Sanford, Nina N. , Shi, Qian , Hein, David , Hall, William A. , Hein, David M , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 10, 2024 | Volume: 117 | Issue: 5 | Pages: 879-889

10.1093/jnci/djae313 | PMID 39656956 Get It

Abstract Background The National Clinical Trials Network (NCTN) is the largest government-sponsored organization in the United States; it is tasked with funding randomized controlled trials in oncology. It is unknown whether there are differences in study design by treatment modality. We evaluated differences in methodology between trials testing radiation therapy (RT) vs systemic therapy. Methods The Clinical Trials Support Unit website was used to identify active randomized controlled trials of systemic therapy or RT across NCTN cooperative groups through December 31, 2023. Studies in disease sites with more than 5 RT trials were included. Each trial’s protocol was reviewed to obtain key design information that was descriptively compared: primary endpoint, hypothesis testing type (superiority vs noninferiority), noninferiority margin, hypothesized effect size, power, and statistical significance level. Results A total of 186 randomized controlled trials (142 systemic therapy, 44 RT) were examined. Comparing primary endpoints, 59.1% vs 26.8% of RT vs systemic therapy trials, respectively, had a primary endpoint of overall survival. Nearly one-third (31.2%) of RT trials were noninferiority vs 6.3% of systemic therapy trials. Among breast cancer trials, 75% of RT studies were noninferiority vs 11.1% systemic therapy. Target effect size, power, and statistical significance level were similar by treatment modality within tumor types and disease settings. Conclusion Among NCTN cooperative group randomized controlled trials, there were marked differences in study design between RT vs systemic therapy trials. A higher benchmark for defining success for RT interventions was observed, with greater emphasis on overall survival as the primary endpoint. This finding may reflect differences in therapeutic mechanism by modality and types of study questions posed.
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
Laetsch, Theodore W. , Voss, Stephan D. , Ludwig, Kathleen , Hall, David , Barkauskas, Donald A. , DuBois, Steven G. , Ronan, Joan, Rudzinski, Erin R. , Memken, Amanda , Robinson, Krystal, Sorger, Joel, Bhatla, Teena, Church, Alanna J. , Fox, Elizabeth , Weigel, Brenda J. , Voss, Stephan D , Reid, Joel M , Crompton, Brian D , Church, Alanna J , Fox, Elizabeth , Weigel, Brenda J , Teachey, David T , Reid, Joel M. , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | December 9, 2024 | Volume: 43 | Issue: 10 | Pages: 1188-1197

10.1200/jco-24-01854 | PMID 39652801 Get It

PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed NTRK fusion–positive solid tumors with response-adapted duration of therapy and local control. METHODS Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability. The primary end point was the objective response rate (ORR) within six cycles in patients with infantile fibrosarcoma (IFS); patients with other histologic diagnoses were analyzed in a separate cohort. Secondary objectives included event-free survival (EFS) and overall survival (OS). RESULTS Thirty-three patients were enrolled: 18 with IFS and 15 with other solid tumors. The ORR within six cycles was 94% (17/18; 95% adjusted CI, 72.7 to 98.6) among children with IFS and 60% (9/15; 95% CI, 32.3 to 83.7) among children with other solid tumors. Six percent (2/33; 95% CI, 0.7 to 22.2) patients developed progressive disease while on therapy. Two-year EFS and OS among these groups were 82.2% (95% CI, 54.3 to 93.9) and 93.8% (95% CI, 63.2 to 99.1) for IFS and 80% (95% CI, 50.0 to 93.1) and 93.3% (95% CI, 61.3 to 99.0) for other solid tumors, respectively. Patients undergoing surgical resection of their tumor had prolonged EFS, with only 1 of 16 such patients experiencing disease progression. Four of 33 patients had dose-limiting toxicities. CONCLUSION Larotrectinib is highly active in patients with newly diagnosed NTRK fusion–positive solid tumors. Larotrectinib should be a frontline option for patients with IFS and other NTRK fusion–positive solid tumors. Local control with surgical resection remains important in the treatment of patients with IFS.
Patch Testing in Solid Organ Transplant Recipients: Experience from a Tertiary Medical Center over 13 Years (2010–2022)
Wang, Katherine , Tolaymat, Leila , Davis, Mark D. P. , Youssef, Molly J. , Yiannias, James A. , Yang, Yul W. , Hall, Matthew R. , Wang, Katherine L , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | December 9, 2024 | Volume: 36 | Issue: 3 | Pages: 216-220

10.1089/derm.2024.0331 | PMID 39653361 Get It

Abstract: Background: It is generally recommended that patients not be on immunosuppressive medications for patch testing, as these medications may suppress delayed-type hypersensitivity and lead to false negative results. There is a paucity of literature describing organ transplant recipients who underwent patch testing. Objective: The aim of this study is to examine patch testing results in solid organ transplant recipients over a 13-year period at our institution. Methods: We performed a retrospective analysis of patch test data from adult transplant recipients at our institution. Transplant patients who underwent patch testing were identified from a clinical patch test database, and a chart review was conducted. Results: Eighteen patients were included in the study. Patients had received kidney, liver, or heart transplants. Seven patients (38.9%) had at least one positive reaction. The highest reaction rates were seen with methylisothiazolinone (12.5%), methyldibromo glutaronitrile (12.5%), and benzalkonium chloride (10.0%). Limitations included small sample size, data from a tertiary referral center, and retrospective analysis. Conclusions: Liver and kidney transplant recipients displayed allergic reactions during patch testing. Patients may benefit from patch testing even if receiving immunosuppressive therapy, but some reactions may be falsely negative because of immunosuppression.
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Cloyd, Jordan M. , Sarna, Angela, Arango, Matthew J. , Bates, Susan E. , Bloomston, Mark, Ferrone, Cristina R., Gambino, Patricia, Goenka, Ajit H. , Hall, William A. , Jayaraman, Shiva , Kambadakone, Avinash, Ko, Andrew , Kooby, David A. , Krishna, Somashekar G. , Larsson, Liliana, Massarweh, Nader N. , Mikhail, Sameh , Palta, Manisha , Petzel, Maria Q. B., Philip, P. A., Mina, Daniel Santa , Sohal, Davendra , Sundaresan, Tilak , Tsai, Susan, Vreeland, Timothy J. , Walston, Steve, Wo, Jennifer Y. , Snyder, Rebecca A. , He, Jin , Tsai, Susan , Krishna, Somashekar G , Santa Mina, Daniel , Bates, Susan E , Bhutani, Manoop S. , Chung, Vincent , Dotan, Efrat , Goodman, Karyn A. , He, Jing , Hogg, Melissa E. , Katz, Matthew H. G. , Khorana, Alok A. , Koay, Eugene J. , Lee, Richard T. , Maitra, Anirban , Muzaffar, Mahvish , O’Reilly, Eileen M. , Reyngold, Marsha , Turner, Kea L. , Washington, Mary Kay , Williams, Terence M. , Snyder, Rebecca A.

Mayo Clinic

JAMA Surgery | December 4, 2024 | Volume: 160 | Issue: 2 | Pages: 172

10.1001/jamasurg.2024.5191 | PMID 39630427 Get It

Importance Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and the standards for optimal delivery of NT have not been defined. Objective To develop consensus best practices for delivering NT to patients with localized PDAC. Design, Setting, and Participants This study used a modified Delphi approach consisting of 2 rounds of voting, and a series of virtual conferences (from October to December 2023) to reach expert consensus on candidate best practice statements generated from a systematic review of the literature and expert opinion. An interdisciplinary panel was formed including 47 North American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterology, integrative oncology, anesthesia, pharmacy, nursing, cancer care delivery research, and nutrition as well as patient and caregiver stakeholders. Main Outcome and Measures Statements that reached 75% agreement or greater were included in final consensus statements. Results Of the 47 participating panel members, 27 (57.64%) were male, and the mean (SD) age was 47.6 (8.2) years. Physicians reported completing training a mean (SD) 14.6 (8.6) years prior and seeing a mean (SD) 110.6 (38.4) patients with PDAC annually; 35 (77.7%) were in academic practice. Final consensus was reached on 82 best practices for delivering NT. Of these, 38 statements focused on pre-NT practices, including diagnosis and staging (n = 15), evaluation and optimization (n = 20), and decision-making (n = 3); 29 statements defined best practices during NT, including initiation (n = 3), delivery of therapy (n = 8), restaging practices (n = 12), and management of complications during NT (n = 6); and 15 best practices were identified to guide treatment post-NT, focusing on surgery (n = 7), pathology (n = 4), and follow-up (n = 3). Conclusions Using a modified Delphi consensus technique, best practice guidelines were developed focusing on the optimal standards for delivering NT to patients with localized PDAC. Given the prognostic importance of completing multimodality therapy, efforts to standardize and optimize the delivery of NT represent an immediate opportunity to decrease care variation and improve outcomes for patients with PDAC. Future research should focus on validating and implementing best practice standards into clinical practice.